"The
Report PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and
Market Analysis to 2023 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Summary
Renal
cell carcinoma (RCC) is among the 10 most frequently occurring
cancers in Western countries. The RCC market is currently dominated
by anti-angiogenic agents and tyrosine kinase inhibitors (TKIs) in
particular, but it will experience dramatic changes over the forecast
period as patents expire and promising new therapies enter the
market. A large share of the RCC market is currently dominated by a
few large companies, but they will struggle to retain these shares as
they are joined by new entrants. One of these new entrants, Opdivo,
is expected to have the largest market share by 2023. The different
lines of treatment will offer up different battlegrounds and niches
for companies, large and small, to compete for. The battle for the
first-line of therapy is expected to be fierce, with three programmed
death protein 1 (PD-1)/programmed death ligand 1 (PD-L1)-containing
combination therapies backed by large companies lining up to compete.
Out of this competition, new standards of care are expected to emerge
for the different lines of treatment. There will also be a number of
unmet needs still remaining at the end of the forecast period, and
with that, the opportunity for pipeline drugs to carve out a niche in
the RCC space.
View Report At
:http://www.marketresearchreports.biz/analysis/761833
Highlights
Key Questions Answered
-
The RCC market is marked by the presence of a number of unmet needs.
What are the main unmet needs in this market? Will the drugs under
development fulfil the unmet needs of RCC market?
-
The late-stage RCC pipeline has therapies targeting different lines
of therapy. Which drugs will have the biggest impact in each RCC
setting? Which of these drugs will have the highest peak sales at the
highest CAGR, and why?
-
Current therapies used to treat RCC include tyrosine kinase
inhibitors and mTOR inhibitors. What will be the impact of the patent
expiry of the current standard of
care?
How will the advent of new therapies change the drug treatment
landscape for RCC? How will new drug combinations change the
treatment paradigm of RCC? What are the key drivers and barriers to
this change?
Key Findings
-
The main drivers of the growth of the RCC market will be the launch
of Opdivo in second-line setting and PD-1 modulator combinations in
the first-line setting. GlobalData forecasts significant patient
uptake for Opdivo, which will supersede tyrosine kinase inhibitors
and mTOR inhibitors to become the SoC in second-line setting.
-
The approval of immunotherapy in monotherapy or in combination with
other agents will partially fulfil key unmet needs in the RCC space:
however, many of these unmet needs will still remain even after these
agents are launched.
-
Another driver of the RCC market is the increasing incidence of RCC
cases within the 8MM. The biggest constrainer of the RCC market is
the launch of generics of tyrosine kinase inhibitors currently
established as standard of care in most markets.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/761833
Scope
- Overview of RCC, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
- Annualized RCC therapeutics
market revenue, average cost of therapy and treatment usage pattern
data from 2013 and forecast for ten years to 2023.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the RCC
therapeutics market.
- Pipeline analysis:
comprehensive data split across different phases, emerging novel
trends under development, and detailed analysis of late-stage
pipeline drugs.
- Analysis of the current and
future market competition in the global RCC therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies
by understanding the trends shaping and driving the global RCC
therapeutics market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the global RCC
therapeutics market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the
global RCC therapeutics market from 2013-2023.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table
of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 24
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and
Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 26
3.2 Clinical Staging 27
3.3 Symptoms 28
3.4 Prognostic Models 29
3.5 Potential Biomarkers 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and
Comorbidities 31
4.3 Global Trends 33
4.3.1 Incidence 33
4.3.2 Survival Rates for RCC -
8MM 35
4.4 Forecast Methodology 36
4.4.1 Sources Used 38
4.4.2 Sources Not Used 41
4.4.3 Forecast Assumptions and
Methods for RCC Diagnosed Incident Cases 41
4.4.4 Forecast Assumptions and
Methods for RCC Five-Year Diagnosed Prevalent Cases 42
4.4.5 Forecast Assumptions and
Methods for RCC by Clinical Stage at Diagnosis 43
4.5 Epidemiological Forecast of
RCC (2013-2023) 44
4.5.1 Diagnosed Incident Cases
of RCC 44
4.5.2 Age-Specific Diagnosed
Incident Cases of RCC 45
4.5.3 Sex-Specific Diagnosed
Incident Cases of RCC 47
4.5.4 Age-Standardized
Diagnosed Incidence of RCC 49
4.5.5 Diagnosed Incident Cases
of RCC by Clinical Stage at Diagnosis 51
4.5.6 Five-Year Diagnosed
Prevalent Cases of RCC 52
4.6 Discussion 53
4.6.1 Epidemiological Forecast
Insight 53
4.6.2 Limitations of the
Analysis 54
4.6.3 Strengths of the Analysis
54
5 Disease Management 56
5.1 Diagnosis and Treatment
Overview 56
5.1.1 Screening and Diagnosis
56
5.1.2 Surgical Management of
RCC 56
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment